Product Pathways - Growth Factors/Cytokines
Human Interleukin-1β (hIL-1β) #8900
|8900LC||50 µg (With Carrier)||---||In Stock||---|
|8900LF||50 µg (Carrier Free)||---||In Stock||---|
|8900SC||10 µg (With Carrier)||---||In Stock||---|
|8900SF||10 µg (Carrier Free)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant human IL-1β (hIL-1β) Ala117-Ser269 (Accession #NM_000576) was produced in E. coli at Cell Signaling Technology.
Recombinant hIL-1β does not have a Met on the amino terminus and has a calculated MW of 17,377. DTT-reduced and non-reduced protein migrate as 18 kDa polypeptides. The expected amino-terminal APVRS of recombinant hIL-1β was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-1β. All lots are greater than 98% pure.
The bioactivity of recombinant IL-1β was determined by its ability to induce IL-8 production by primary human fibroblasts. The ED50 of each lot is between 5-20 pg/ml.
The purity of recombinant hIL-1β was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-1β and staining overnight with Coomassie Blue.
The production of IL-8 by primary human fibroblasts cultured with increasing concentrations of human IL-1β was assessed. Media from cells incubated with IL-1β for 24 hours was collected and assayed for IL-8 by ELISA and the OD450-OD650 was determined.
Western blot analysis of extracts from MCF-7 cells, untreated or treated with hIL-1β for 20 minutes, using Phospho-NF-κB p65 (Ser536) (93H1) Rabbit mAb #3033 (upper) and NF-κB p65 Antibody #3034 (lower).
Less than 0.01 ng endotoxin/1 μg hIL-1β.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-1β. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
IL-1β is a pro-inflammatory cytokine produced predominantly by activated monocytes and epithelial cells (1). Precursor IL-1β is cleaved by caspase-1 and mature IL-1β is then secreted (1-3). Target cells include macrophages and many other cell types. Signaling by IL-1β involves IL-1β binding to IL-1 accessory protein (IL-1-AcP) and then the complex binds to IL-1RI (1,2). Signaling is through activation of MAP kinase and NF-κB pathways (1,2). IL-1β also binds to IL-1RII that lacks an intracellular signaling domain and thereby serves as a high affinity decoy receptor. IL-1β binding to IL-1RI is inhibited by the negative regulator, IL-1R antagonist (IL-1Ra). IL-1Ra binding to IL-1RI does not signal and serves to block IL-1β signaling. IL-1β plays critical roles in the acute phase response and sepsis (1-3).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.